Advanced Gene Therapies Will Drive Global Rare Disease Growth
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 20 Analysts
Published
04 Aug 25
Updated
16 Aug 25
AnalystHighTarget's Fair Value
US$128.00
76.8% undervalued intrinsic discount16 Aug
US$29.69
1Y
-44.0%7D
7.8%